Back to top

Analyst Blog

On July 8, we have updated our research report on St. Jude Medical Inc. (STJ - Analyst Report), which currently looks attractive with solid one-year return of 52.5%, much higher than the S&P 500 return of 19.7% as well as returns of 22.9% and 38.7% posted by the company’s peers Medtronic, Inc. (MDT - Analyst Report) and Boston Scientific Corporation (BSX - Analyst Report), respectively.

On Jul 7, shares of the St. Paul, MN-based medical devices major reached a new lifetime high of $71.90. We believe global demographic trends, ageing population in developed nations and the rapid urbanization of developing countries should support company growth.

We are particularly encouraged by St. Jude Medical’s recent acquisition of privately-held CardioMEMS, Inc. at the beginning of last month. With the closure of the CardioMEMS acquisition, St. Jude Medical expects accelerated growth in its cardiovascular segment.

The CardioMEMS HF System is a first-of-its-kind U.S. Food and Drug Administration (FDA)-approved heart failure monitoring device that has been proven to significantly reduce heart failure-related hospitalizations. It has set a new treatment paradigm for heart failure that reduces the need for hospitalizations and improves the quality of life for patients.

The CardioMEMS HF System has already obtained the CE Mark approval in the EU. St. Jude Medical now plans to initiate the system’s strategic launch in the U.S.

Recently, St. Jude Medical also received the 2014 Innovation Award at Cardiostim 2014, the 19th World Congress in Cardiac Electrophysiology and Cardiac Techniques for its Nanostim leadless pacemaker.
    
A congress committee of electrophysiologists has chosen St. Jude Medical’s Nanostim leadless pacemaker for the award being the most innovative product in electrophysiology and cardiac technique.

A few days back, St. Jude Medical also resolved the FDA warning letter regarding the company’s Sylmar facility in California. Last year, FDA had warned St. Jude Medical for serious violations at the plant, which included a failure to validate testing methods.

For full year 2014, St. Jude Medical upgraded its revenues guidance to the range of $5,610 to $5,760 million from the prior range of $5,600 million to $5,750 million. It also upgraded its adjusted earnings per share guidance to $3.95–$4.00 from the prior range of $3.94–$3.99. The current Zacks Consensus Estimates for earnings per share and revenues for the year are pegged at $3.98 and $5,700 million, respectively.

Currently, St. Jude carries a Zacks Rank #3 (Hold). A better-ranked stock in the medical products industry is Wright Medical Group Inc. (WMGI - Analyst Report), which carries a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%